Investors have begun to eye companies in the healthcare and biotechnology sectors that are developing technologies with artificial intelligence at their core, in order to contribute to the faster discovery of new treatments.

According to recent data from the Crunchbase data collection platform, last year more than $7.5 billion was channeled to companies that utilize artificial intelligence in the healthcare sector, with an emphasis on medical services as well as the drug development sector, an amount still lagging the 2021 record ($13.7 billion).

However, more and more investors have recently been pouring capital into this sector, with Crunchbase pointing out that in 2025 “the year has started strongly” and that the investment community has mobilized almost $1.7 billion in 50 deals in less than two months.

Another one has been added to them: It is Achira.ai, a company with Greek DNA, co-founded by Theofanis Karaletsos. A few days ago, Achira secured 31.4 million euros in funding, including from Nvidia’s investment arm, NVentures, just a year-and-a-half after its founding.

Using artificial intelligence and a combination of physical simulations, the startup accelerates the discovery processes of new molecules, thereby contributing to the faster development of new treatments.

In addition to the technological giant, the newly founded company was backed by the Dimension investment fund, Amplify Partners and the venture capital fund Compound.

“So far, there is no clear indication that investors will slow down their investments in companies that combine artificial intelligence with the healthcare sector. On the contrary, we will probably see an increase, as more and more startups in the health and biotechnology sectors incorporate AI,” reports Crunchbase.

Greek companies have also joined the fray of these investments and, above all, the battle of discovering new drugs, some of which maintain a wide presence in this country. Thrasyvoulos Karydis’ company DeepCure has discovered a chemical molecule that aspires to develop its own drugs using artificial intelligence to treat autoimmune and autoinflammatory diseases, such as rheumatoid arthritis, psoriasis etc.

https://www.ekathimerini.com/economy/1263000/nvidia-supports-greek-startup/#